Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.82 |
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | MITF | O75030 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 11/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.81 |
| ▸ | HPGD | P15428 | 5/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | HTT | P42858 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | PPARG | P37231 | 1/20 | 0.78 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.78 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510185 | 0.91 | MEN1 (0.98) | MEN1KMT2ARAB9AMITFMAPT | |
| SCHEMBL837705 | 0.86 | MAPT (0.80) | MEN1KMT2ARAB9AMAPTALDH1A1 | |
| SCHEMBL4531290 | 0.86 | PIK3CG (1.00) | MEN1KMT2ARAB9AMITFMAPT | |
| SCHEMBL837865 | 0.85 | MAPT (0.73) | MEN1KMT2ARAB9AMITFMAPT | |
| SCHEMBL4534326 | 0.85 | MEN1 (0.83) | MEN1KMT2ARAB9AMITFMAPT | |
| SCHEMBL4512539 | 0.85 | MEN1 (0.83) | MEN1KMT2ARAB9AMITFMAPT | |
| SCHEMBL23270901 | 0.85 | MAPT (0.98) | MEN1KMT2ARAB9AMAPTALDH1A1 | |
| SCHEMBL4532774 | 0.84 | MEN1 (0.85) | MEN1KMT2ARAB9AMITFMAPT | |
| SCHEMBL22703718 | 0.84 | MAPT (0.75) | MEN1KMT2ARAB9AMAPTALDH1A1 | |
| SCHEMBL4524238 | 0.82 | MEN1 (0.84) | MEN1KMT2ARAB9AMITFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11298348-B2 | Combination treatment of sarcoglycanopathies | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE) (FR) | 2022-04-12 | — | — | US | claimed |
| US-20210059999-A1 | COMBINATION TREATMENT OF SARCOGLYCANOPATHIES | UNIVERSITE D'EVRY-VAL-D'ESSONNE (FR) | 2021-03-04 | — | — | US | claimed |
| EP-3737375-A1 | COMBINATION TREATMENT OF SARCOGLYCANOPATHIES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-18 | — | — | EP | claimed |
| EP-2925317-B1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIV DEGLI STUDI PADOVA (IT) | 2019-09-04 | — | — | EP | claimed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | claimed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | claimed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | claimed |
| EP-2925317-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | Università Degli Studi Di Padova (IT) | 2015-10-07 | — | — | EP | claimed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-11298348-B2 | Combination treatment of sarcoglycanopathies | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE) (FR) | 2022-04-12 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | MEN1 3957/4885KMT2A 3813/4885RAB9A 687/4885 |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | MEN1 4212/4885KMT2A 3932/4885RAB9A 789/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | MEN1 4634/4885KMT2A 4258/4885RAB9A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.